JP2015509972A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509972A5
JP2015509972A5 JP2014561514A JP2014561514A JP2015509972A5 JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5 JP 2014561514 A JP2014561514 A JP 2014561514A JP 2014561514 A JP2014561514 A JP 2014561514A JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5
Authority
JP
Japan
Prior art keywords
compound
formula
metal salt
lactose
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561514A
Other languages
English (en)
Japanese (ja)
Other versions
JP6189874B2 (ja
JP2015509972A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2013/050623 external-priority patent/WO2013136075A1/en
Publication of JP2015509972A publication Critical patent/JP2015509972A/ja
Publication of JP2015509972A5 publication Critical patent/JP2015509972A5/ja
Application granted granted Critical
Publication of JP6189874B2 publication Critical patent/JP6189874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561514A 2012-03-13 2013-03-13 新規製薬学的製剤 Expired - Fee Related JP6189874B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13
US61/610,023 2012-03-13
US61/610,012 2012-03-13
PCT/GB2013/050623 WO2013136075A1 (en) 2012-03-13 2013-03-13 Novel pharmaceutical formulations

Publications (3)

Publication Number Publication Date
JP2015509972A JP2015509972A (ja) 2015-04-02
JP2015509972A5 true JP2015509972A5 (OSRAM) 2016-04-14
JP6189874B2 JP6189874B2 (ja) 2017-08-30

Family

ID=49160309

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561514A Expired - Fee Related JP6189874B2 (ja) 2012-03-13 2013-03-13 新規製薬学的製剤
JP2014561515A Pending JP2015509973A (ja) 2012-03-13 2013-03-13 結晶性pi3キナーゼ阻害剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性pi3キナーゼ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014561515A Pending JP2015509973A (ja) 2012-03-13 2013-03-13 結晶性pi3キナーゼ阻害剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性pi3キナーゼ阻害剤

Country Status (35)

Country Link
US (3) US20150099768A1 (OSRAM)
EP (2) EP2834244B1 (OSRAM)
JP (3) JP6189874B2 (OSRAM)
KR (2) KR20140141596A (OSRAM)
CN (2) CN104302650B (OSRAM)
AU (2) AU2013234080B2 (OSRAM)
CA (2) CA2864643A1 (OSRAM)
CL (2) CL2014002386A1 (OSRAM)
CO (2) CO7051030A2 (OSRAM)
CR (2) CR20140416A (OSRAM)
CY (1) CY1118565T1 (OSRAM)
DK (1) DK2834244T3 (OSRAM)
EA (2) EA023715B1 (OSRAM)
EC (2) ECSP14018142A (OSRAM)
ES (2) ES2600705T3 (OSRAM)
GT (2) GT201400182A (OSRAM)
HR (1) HRP20161383T1 (OSRAM)
HU (1) HUE029420T2 (OSRAM)
IL (2) IL233883A0 (OSRAM)
IN (2) IN2014MN01998A (OSRAM)
LT (1) LT2834244T (OSRAM)
MX (2) MX355299B (OSRAM)
MY (1) MY171125A (OSRAM)
NI (2) NI201400100A (OSRAM)
NZ (2) NZ628072A (OSRAM)
PE (2) PE20142342A1 (OSRAM)
PH (2) PH12014501713A1 (OSRAM)
PL (1) PL2834244T3 (OSRAM)
PT (1) PT2834244T (OSRAM)
SG (2) SG11201404519UA (OSRAM)
SI (1) SI2834244T1 (OSRAM)
TW (2) TWI586378B (OSRAM)
UA (1) UA115544C2 (OSRAM)
WO (2) WO2013136076A1 (OSRAM)
ZA (2) ZA201407374B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ES2600705T3 (es) 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MA40250A (fr) 2014-07-04 2017-05-10 Lupin Ltd Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US20190117568A1 (en) * 2016-04-15 2019-04-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Inhaled Preparation Of Isoglycyrrhizic Acid Or Salt Thereof, And Use In Preparing Drugs For Treating Respiratory System Diseases
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
RU2221552C2 (ru) 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
WO2000053157A1 (en) 1999-03-05 2000-09-14 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Nadシンテターゼ阻害剤およびその使用
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
AU2007347115A1 (en) 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CA2652886A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
US8022088B2 (en) 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009012066A (es) * 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010281265A1 (en) 2009-08-05 2012-03-22 Versitech Limited Antiviral compounds and methods of making and using thereof
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) * 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) * 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
US20130157991A1 (en) * 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
PL2621494T3 (pl) 2010-09-30 2019-04-30 Chiesi Farm Spa Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) * 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
ES2600705T3 (es) 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos

Similar Documents

Publication Publication Date Title
JP2015509972A5 (OSRAM)
JP2015509973A5 (OSRAM)
NZ627963A (en) Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
AU2020203497B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
JP2018534348A5 (OSRAM)
JP2018035160A5 (OSRAM)
JP2012041365A5 (OSRAM)
JP2013541595A5 (OSRAM)
JP2014037426A5 (OSRAM)
JP2017504635A5 (OSRAM)
JP2014532638A5 (OSRAM)
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
RU2016123828A (ru) Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
JP6243265B2 (ja) ロスバスタチン含有医薬製剤
JP2009040767A5 (OSRAM)
JP2017507980A5 (OSRAM)
RU2016106336A (ru) Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
NO20070952L (no) Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
JP2020500168A5 (OSRAM)
JP2011500819A5 (OSRAM)
JP2020510061A5 (OSRAM)
JP2013526579A5 (OSRAM)
JP2018528238A5 (OSRAM)